Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management Syste ...

Insulet attained several landmarks with regard to extending Omnipod’s market access. In the third quarter, the company successfully broadened the Omnipod DASH coverage for commercial, Medicare ...

ACTON, Mass., June 20, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the appointment of Eric ...

Additionally, the company made the full commercial launch of the system with G7 compatibility in the United States and rolled out the Omnipod 5 App through a limited market release for iPhone.

Tandem’s new Mobi pump (set for full commercial launch in early 2024) might be its greatest hope. However, Mobi remains a tubed pump, and we think Omnipod 5 still offers significant differentiation.

Insulet Corporation PODD recently announced the commercial introduction of its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for people with type 1 diabetes (T1D) who are two years of ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...

Following a successful limited market release, the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now fully available with Dexcom G6 and Abbott FreeStyle Libre 2 Plus in these countries ...

Insulet develops, manufactures and distributes the Omnipod System, the market-leading tubeless insulin management system, currently used by over 110,000 people living with diabetes worldwide ...